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ABSTRACT
Bone Fracture Toughness of Estrogen Deficient Rabbits
Matthew S. Smith
Bone mass is commonly used as an indicator of fracture risk. It has been shown in
numerous studies that bone loss causes increased bone fragility and risk of fracture. It has also been
shown that 50% of patients with osteoporotic vertebral compression fractures have the same bone
mass as normal age matched controls. Thus, bone mass alone is not the only indicator of bone
quality and ability to resist fracture.
The objective of this study was to qualitatively assess bone’s mechanical and
histomorphometric changes with drug treatment, and estrogen deficiency, using fracture toughness,
femoral neck fracture and histomorphometric analysis in an ovarectomized rabbit model.
No significant differences were found in fracture toughness, porosity, or femoral neck
ultimate strength for any treatment group, which may have be from a lack sufficient time for the
difference caused by estrogen deficiency and drug treatment to manifest in the rabbit model.
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CHAPTER 1: INTRODUCTION
1.1 Project Overview
Bone is in a constant state of change with the processes of remodeling and modeling,
which is different from the growth process, since it is an overturning and renewal of a mature
skeleton. As a bone models and/or remodels it becomes more porous, but may have an
increase in overall bone mass. Due to this unique property, fracture toughness, a well known
engineering measure of a predamaged material’s resistance to fracture or crack propagation,
is a good indicator of bone quality.
Bone mass is commonly used as an indicator of fracture risk, and Dempsey and Linsey
(1993) have shown that bone loss causes an increased risk of fracture and fragility in general,
but Avioli (1987) has reported that 50% of people with osteoporotic vertebral compression
fractures have the same bone mass as normal age matched controls. This would imply that
bone mass is insufficient as an indicator of bone quality and ability to resist fracture.
The purpose of this project is to qualitatively assess the fragility of bone by use of
histomorphometry and fracture toughness testing, as well as bone mineral density testing
(DXA), to demonstrate the ability of bisphosphonates to decrease the fragility, or maintain
the fragility at a pre-ovarectomized state.
1.1.1 The Cost of Osteoporosis
The National Institute of Health estimates that the annual cost of osteoporitic and
associated fractures in the United States to be $17 billion, or $47 million per day (NIH,
2003). The annual cost is approximately 0.2% of the United States Gross Domestic Product
(GDP) for the year 2000, which is greater than the 2000 GDP of such countries as Costa Rica
($14.7 billion), El Salvador ($11.0 billion), and Oman ($16.7 billion) (EIA, 2002). The
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number of hip fractures, which is the second most common osteoporotic fracture, has been
estimated to rise to 6 million per year by 2050 (Genant et al, 1999).
1.1.2 Clinical Significance
Osteoprosis is a major problem for approximately 44 million Americans, 68%
of whom are women. Half of woman with osteoporosis sustain some kind of
osteoporitic fracture (Stevenson, 1990). One out of two women and one out of eight
men over the age of fifty will have a fracture related to osteoporosis. The annual
fracture total is approximately 1.5 million with : 300,000 hips, 700,000 vertebral
fractures, 250,000 wrists, and 300,000 other fractures, such as ribs, shoulders, etc.
The breakdown of these fractures can be seen in figure 1 (NIH, 2003).

Other
19%

Hip
19%

Wrist
16%

Vertebral
46%

Figure 1.1.2-1: Fracture Types and Percentages Related to Osteoporosis (adapted from NIH
ORBD data) (NIH, 2003)

Cortical bone fragility has been implicated in debilitating conditions such as
osteoporitic fracture, fatigue fracture, stress fracture, and loosening of prosthesis, and
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the loss of cortical bone has been identified as a key feature contributing to femoral
neck fracture.
Crabtree et al. (2001) concluded from a study of intracapsular hip fracture
patients that generalized bone loss accounts for less than about 15% of fracture risk
and that a loss of cortical bone thickness and increased intracortical porosity is the
key feature to hip fracture risk.
1.2 Objectives
To better understand the effects of estrogen deficiency and various treatments for
osteoporosis on the fracture toughness of bone, three objectives were set:
1. Perform histomorphometry to quantify bone parameters (porosisty, osteon density,
osteon area, etc) for comparison.
2. Perform mechanical testing (fracture toughness and femoral neck fracture) on the
bones to find strength and toughness values for comparison.
3. Compare and correlate the histomorphometric and mechanical data.
1.3 Hypotheses
The following hypotheses were made:
1. There is a significant difference in fracture toughness between all
Ovarectomized (Ovx) and Normal specimens.
2. There is a significant difference in the fracture toughness between Ovx and
Ovx with Residronate (Ovx – Ris) treatment specimens, with the Ovx-Ris
specimens approaching but not reaching the fracture toughness of the Normal
group.
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3. There is a significant difference in the structural properties of the femoral
neck between the groups, with the values of the Ovx-Ris treatment group
approaching that of the Normal group.
4. There is a significant difference in the dynamic and static histomorphometric
that will correlate with the fracture toughness and femoral neck fracture
values, with the Ris group approaching the values of the Normal group.
1.4 Anatomical Background
Bones are the main structural components of the body. They provide support
for the weight of the body, resist dynamic loads caused by the movement of the body,
protect the nervous system and organs, provide levers for the skeletal muscles, and
are reserves for various substances necessary for bodily function, such as calcium.
The skeleton does all of these things with a high level of adaptability, making the
skeleton a machine of unparalleled complexity. From an engineering or design
standpoint, it would be difficult to imagine creating a structure which satisfies these
needs, and even more difficult to create such a structure.
Bone is a unique material. Unlike most engineering materials, it cannot be
considered homogeneous, bone is often assumed to be transversely isotropic, which is
similar to many composite materials. Unlike all engineering materials, it has the
ability to repair damage and adapt to various loading situations, using a constant state
of tearing down and renewal, through resorption and formation.
1.4.1 Body Definitions
It is beneficial to know some of the anatomical terms that will be used in this
paper particularly in chapters 4 and 5. These terms are general directional, sectional,
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and location terms, and although they are not related to engineering, they are
necessary in the study of anatomy and physiology.
Figure 1.4.1 shows the important planar definitions for the rabbit and most
quadrupeds, which have some notable differences to bipeds, such as humans.

Figure 1.4.1 – 1: Schematic representation of anatomical terms for the rabbit (Wingerd,
1985).

The dorsal side is simply the back side. The reader may notice that the dorsal
and superior sides are equivalent for a quadruped, but are not the same for a biped (ie
humans); this may cause some confusion for those familiar with only human
anatomy. The anterior (cranial), caudal (posterior), and ventral (inferior) sides may
also cause confusion, because the terms are the same, as shown for a quadruped, but
do not correspond for bipeds. The difficulty can be eliminated by thinking of the
directions (superior, inferior, cranial, and caudal) separately from the planes (anterior,
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posterior, dorsal, and ventral). For example, dorsal means the plane of the back, and
can be easily seen as the plane looking down on the top of the animal, if the animal is
standing normally. The superior direction is simply that it is above another structure,
this is not related to body structure, per se, and just means to be above something
else. The other pairs of correlating planes and directions make sense as well, when
thought of in this way.

Figure 1.4.1-2: Diagram of the rabbit skeleton (Wingerd, 1985).
Figure 1.4.1-2 shows the rabbit skeleton. The bones used in this study were
the tibia and femur, which are the two main long bones of the hind legs of the rabbit.
The fibulas were also removed during the dissection, because unlike humans, they are
fused to the tibias, but were eventually discarded during machining.
Bone anatomy necessitates the definition of more terms. This project uses the
femur and tibia, so the effort of definition will focus on these. Proximal is a
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direction, relative to a particular point, going towards the midpoint of the body. By
this definition, the proximal end of a long bone would be the end that is towards or
closest to the midpoint, which for the femur would be the head and neck region, and
for the tibia it would be the condyles that make up part of the knee. The midshaft of a
long bone is the general area that is approximately halfway between the two end
points of the long bone, which is often thought of as a shaft even though it does not
usually have the uniform cylindrical shape associated with a shaft. The term
definitions can be seen in figures 1.4.1-3 and 1.4.1-4, where the arrows are indicative
of the directional definition from the midshaft.

Proximal

Mid-shaft

Distal

Figure 1.4.1-3: Definition of locations and Anatomy of the Femur (Wingerd, 1985)
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Figures 1.4.1-3 and 1.4.1-4 also show some of the important bony landmarks
of the femur and tibia.

Proximal

Mid-shaft

Distal

Figure 1.4.1-4: Direction and Anatomy Illustration of the tibia (Wingerd, 1985)

1.4.2 Macrostructure of Bone
Macroscopically bone is generally divided into two types: cortical and
trabecular bone. Cortical bone is often referred to as compact bone, and trabecular
bone is known as cancellous or spongy bone. The different types of structures can
easily be seen in the figure 1.4.2-1, where cortical bone is the dense region and
cancellous is the latticework region, that makes up most of the femoral head and
neck, with a outer cortex of cortical bone, but the shaft is mainly cortical bone.
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Trabecular
Bone

Cortical
Bone

Figure 1.4.2-1: Cross-section of the Proximal Femur Showing Cortical and Cancellous Bone
(Albright and Skinner, 1987, with labels added)
The structure of having a compact outer shell with an inner woven structure
allowing for optimal mechanical function under loading is common in all bones. The
structure of bone adapts to the loading that the bone is subjected.
1.4.3 Microstructure of Bone
Microscopically, two types of bone can be distinguished, woven and lamellar
bone. Woven bone is characterized by an irregular array of loosely packed collagen
fibrils resembling a crudely woven cloth. This type of bone is initially formed in the
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embryo and during child development, but is only found in small amounts in the adult
skeleton, except under conditions of rapid bone formation, such as fracture healing
and diseases such as Paget’s disease. In the normal adult skeleton, both the cortical
and trabecular bone is made of parallel collagen fibers, organized in a lamellar
pattern.
Bone consists of two major components: the matrix of collagen fibers and four
types of bone cells. The matrix is the main structural referent of the bone, which has
a characteristic distribution. The outer part of the bone consists of a shell or cortex of
cortical bone that generally forms the overall conformation of the bone and within
this structure lays the trabecular bone.
The cortical bone is divided into three regions. The outer most region is
known as periosteal bone. The middle and most dominant region is the Haversian
bone, which is a region of bone containing the Haversian system, and the inner layer
called subcortical bone.
Haversian bone consists of hollow cylinders made of concentric lamellae with
a vascular canal in the center, which is called an osteon. The diameter of an osteon is
approximately 200 µm regardless of species, because the maximal transport distance
for nutrients is approximately 100 µm.
The Bone Matrix
Bone matrix has four major molecular components: collagen, noncollagenous
proteins, nonprotein organic material, and mineral crystals resembling
hydroxyapatite, with the chemical structure Ca10(PO4)6(OH)2.
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Collagen is the most abundant organic protein making up 90% of the organic
matrix. The collagen fibers are bundled into a complex three-dimensional structure
similar to rope that form a lamellae with the collagen fibers running parallel, with the
long axis being at right angles in adjacent lamellae. Collagen has a triple helix
structure, which can be though of as like a rope, which gives bone its tensile strength.

Figure 1.4.3-1: Composition of Cartilage, Fibrocartilage, and Bone (Albright, ).
The remainder of the organic matrix is closely associated with the collagen
fibers and is dependent on the orientation of the collagen fibers. The noncollagenous
proteins
Mineral makes up approximately 65% of the dry weight of bone, and is made
of very small crystals of the dimensions 200-400 x 35-75 x 10-40 Ǻ in the shape of
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plates. These plates are located within and between the collagen fibers in such a way
to give the bone its compressive strength and stiffness, which is similar to a chopped
fiber composite.
The minerals are laid down during formation of new bone. Such substances
as calcein, tetracycline, polyphosphates, and bisphosphonates have an affinity for
calcium phosphate, and are laid down in areas of new bone formation. This property
is what makes marking for dynamic histomorphometry possible, which will be
explained in later chapters.
Osteoclasts
Osteoclasts are multinucleated cells and are known to be the primary cell
responsible for bone resorption, or the breakdown of bone. The task of resorbing
bone is accomplished within a closed microenvironment, which is between the cell
and the bone surface, as can be seen in figure 1.4.3-2.
Osteoclasts have proton pumps on the side attached to the bone, which is
called the ruffled border. The osteoclast can be thought of as an upside down cup on
a saucer, which leaves a space between the bone and the cell. The proton pumps of
the osteoclast pumps protons into this enclosed space, which causes an enclosed
acidic region (pH of approximately 4) that dissolves the bone matrix. The cell also
pumps various enzymes into the enclosed space as well, such as cathespins, and
possibly collegenase, which dissolves the collagen matrix.
There are three main ways of controlling bone resorption, which are:
recruitment of new osteoclasts, lifespan of new osteoclasts, which is determined by
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apoptosis, and the regulation of the mature osteoclasts. All three of these processes
seem to be influenced by cells of the osteoblastic lineage.

Microenvironment
with ruffled edge

Figure 1.4.3-2: Diagram of an osteoclast (Fleisch, 2000, with additional label)

Figure 1.4.3-3: Role of Osteoblastic cells on Osteoclast’s and therefore bone resorption
(Fleisch, 2000).
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These cells are varied in size and are characteristically seen in lacunae of
resorbed bone.
Osteoblasts
Osteoblast comes from the two Greek words osteon, which means bone, and
blastos, which means germ. Osteoblasts are mononucleated cells and are primarily
responsible for bone formation, or rather the synthesis of the organic components of
the bone matrix (i.e. type I collagen, proteoglycans, and glycoproteins). Osteoblasts
are derived from mesenchymal progenitors, and lay down the unidirectional organic
matrix, which is later mineralized.
The time between the laying down and calcification steps means that there is a
layer of uncalcified bone under the osteoblast. The uncalcified seam that is left by the
osteoblast is thin when bone formation rate is decreased, and it is widest when
mineralization is delayed.
The osteoblasts can be found on the bone surface and have the appearance of
epithelium, which is why they are often classified as bone lining cells, when they are
inactive.
Bone Lining Cells
Active osteoblasts and bone lining cells form a membrane on the bone
surface. Bone lining cells are osteoblasts that are not actively forming bone. When
the osteoblast is inactive, they are flat and found on the bone surface. The inactive
osteoblasts are called bone lining cells because of the characteristic of osteoblasts
appearing like epithelial cells, which are lining cells in the gastrointestinal track.
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Osteocytes
Osteocytes are the osteoblasts that have been completely embedded in the
bone matrix. Osteocytes are the most abundant cell found in bone, but their exact
purpose is still poorly understood. These cells are in the lacunae and are connected to
each other and to osteoblasts. It is theorized that there is signaling between bone
cells, and that osteocytes are the cells that sense the mechanical stimulation.
1.5 Bone Modeling and Remodeling
The skeleton serves many mechanical, metabolic, and protective
functions. The most obvious functions are mechanical support and protection. Bones
are often mistakenly thought of as dead or unchanging structures, but bone is a living,
metabolically active, and highly organized tissue that is in a constant state of flux
through processes of resorption and formation. The osteoblasts and osteoclasts are in
opposition to each other in a cycle called the resorption/ formation cycle (R/F). The
rate of these processes lends itself to this widely held misconception, because the
processes are too slow, or too imbalance for them to be seen macroscopically, with
the naked eye, except over a long period of time and/or some disease state.
Both cortical and cancellous bone undergoes remodeling, in which old bone is
torn down or resorbed, and new bone is built of formed in its place. This process is
very important in damage repair, and in keeping the skeleton strong. It is very
important in the bones adaptation to loading, since the bones will reform in a new
architectural formation to most optimally handle the loading environment, or the
particular loading parameters present on the bone.
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In adults, bone remodeling accounts for more than 90% of normal bone
turnover. In normal individuals, the remodeling space is approximately 6-8% of
skeletal volume (Parfitt, 1980).
1.5.1 R/F Balance Implications in Bone Fragility
The resorption/ formation balance is significant in the net amount of bone
mass and/or microstructructural changes, such as porosity.
Normal bone has a balance between the amount of bone being resorbed and
the amount being formed, for a net change of approximately zero. As people age, the
osteoclasts start to slightly outpace the osteoblasts, so skeletal mass decreases, thus
fracture risk increases. Diseases such as osteoporosis are from an imbalance of this
process. The R/F balance is particularly skewed in women after menopause.
1.5.2 Bone Mass and Bone Fragility
Many studies have shown that bone, rather human or other animal, from
disuse (paralysis, suspension, immobilization, etc.) and/or sex hormone deficiency
(ovarectomy or oophorectormy) results in loss of bone mass (Smith 1989;Weinreb,
1989; Saville, 1969; Schoutens, 1984; Wronski, 1985; Okumra, 1986; Bain, 1990;
Cao, 2001). Decreased bone mass in humans has been shown to be an indicator of
increased fracture risk (Dempster, 1993), but Avioli (1987) has reported that 50% of
osteoporotic vertebral compression fractures have the same bone mass as normal age
matched controls.
Bone mass is not the only change in bone during resorption and formation.
The architecture of the bone is also changed. Patients with osteoporotic fractures are
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found to have larger osteons with larger Haversian canals and a lower osteon density
than patients without a fracture (Barth 1992). The change in structure at a
microscopic level may not be seen in the current tests available for bone mineral
density or bone mass testing, so a new technique is needed to test for fracture risk.
1.6 Bisphosphonates
Various drugs have been used for the treatment of osteoporosis. Two of the
major categories of treatment are Parathyroid Hormone, Hormone Replacement
Therapy, and Bisphosphonates. This project focuses on the use of bisphosphonates,
because of their widespread use, FDA approval for osteoporosis prevention and
treatment, and the proven safety and effectiveness in clinical trials.
The first report of the biological characteristics of bisphosphonates appeared
in 1968, from earlier studies of inorganic pyrophosphates (Fleisch, 2000).
Bisphosphonates, which were formerly called diphosphates, are analogs of
pyrophosphate, but has a carbon joining the two phosphors instead of an oxygen, as in
the pyrophosphate. The carbon is bonded to two other groups to fill it octet and has
the form shown in figure 1.6.3-1. The two side groups (R1 and R2) are what make
each bisphosphonate unique; figure 1.6.3-2 shows the side groups of the FDA
approved drugs, and their corresponding names and manufactures.

Figure 1.6.3-1 General Chemical Structure
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Table 1.6.3-1: FDA approved bisphosphonates for the treatment and prevention of
osteoporosis in postmenopausal women and their chemical structure (Adapted from
Fleisch, 2000).
Name

Brand
Manufacture Chemical Structure
Name
Alendronate Fosamax Ambiogen;
Merck,
Sharp &
Dohme

Residronate

Actenol

Proctor &
Gamble

Bisphosphonates are commonly used in the treatment of osteoporosis,
glucocorticoid-induced osteoporosis, hypercalcemia of malignancy, Paget's disease,
heterotopic ossification, and osteolytic bone metastases of breast cancer or multiple
myeloma.
There are currently only two bisphosphonates that are FDA approved for the
treatment of osteoporosis, which are Alendronate and Risedronate, there are four
other bisphosphonates that are also commonly used in the treatment of bone loss, but
are not FDA approved for osteoporosis treatment.
One drug that is FDA approved for the treatment and prevention of
osteoporosis in postmenopausal women is risedronate, which is the type of
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bisphosphonates used in this study. Several studies have shown that residronate is
effective in increasing bone mineral density (BMD), as shown in tables 1.6.3-2.
Several studies have shown the effectiveness of Alendronate and are included in table
1.6.3-3 for the purpose of completeness.
Table 1.6.3-2: Effects of Risedronate Treatment on BMD (adapted from Cummins, et al,
with additions)
Author

N

Harris, et al., 1999

2458

Reginster, et al, 2000

1226

Geusens, et al. 1999

9497

Fogelman, et al, 2000

543

Mortensen, et al, 1998

111

Fleisch, 2000

large

Mean Increase (%) in BMD in Treatment
Group vs. Placebo
L-spine:
4.4
Femoral Neck:
2.8
L-spine:
5.9
Femoral Neck:
3.1
L-spine: (2.5 mg dose)
5.37
(5.0 mg dose)
7.02
Femoral Neck: (2.5 mg dose)
2.11
(5.0 mg dose)
3.24
L-spine: (2.5 mg dose)
1.4
(5.0 mg dose)
4
Femoral Neck: (2.5 mg dose)
1.9
(5.0 mg dose)
2.3
L-spine: (5 mg cyclic dose)
2.7
(5 mg daily dose)
5.7
L-spine: (5 mg daily dose)
4.3 – 5.8
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Table 1.6.3-3: Effects of Alendronate on BMD in Postmenopausal Woman (adapted from
Cummins, et al, with additions)
Author

N

Liberman et al, 1995

994

Black et al, 1996

2047

Cummings et al, 1998

4432

Pols et al, 1999

1908

Hosking et al, 1998

1609

McClung, et al, 1998

447

Ravn et al, 1999

1609

Mean Increase (%) in BMD in Treatment
Group vs. Placebo
L-spine:
8.8
Femoral Neck:
5.9
L-spine:
6.1
Femoral Neck:
4.1
L-spine:
6.6
Femoral Neck:
4.6
L-spine:
4.9
Femoral Neck:
2.5
L-spine: (2.5 mg dose)
3.1
(5.0 mg dose)
4.6
Total Hip: (2.5 mg dose)
2.2
(5.0 mg dose)
2.7
L-spine: (2.5 mg dose)
6.39
(5.0 mg dose)
7.45
Total Hip: (2.5 mg dose)
4.09
(5.0 mg dose)
5.41
Femoral Neck: (5 mg + placebo) 1.6
(5 mg)
4.3

The action of Bisphosphonates on the process of bone resorption and
formation is not well known, but there are theories of how the bisphosphonates effect
the osteoclasts, which can be regulated by four ways: inhibition of recruitment,
inhibition of osteoclast adhesion, shortening of the osteoclast lifespan, and/or
inhibition of the osteoclast activity.
1.7 Validity of the Animal Model
1.7.1 Introduction
Animals are invaluable assets in medical research, since they allow for the study of
medical and biological processes in a living system without harming humans. The use of
animals allows for the study of things that are impossible, immoral, or unethical to study
in humans. For example, chemical exposures are often studied using animals, which
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would be considered reprehensible to conducting on humans and would be similar to
some of the crimes against humanity committed by the Nazis during World War II.
The type of study being undertaken often makes the use of animals necessary, but
great care must be taken in the selection of the animal model and the interpretation of
these models.
1.7.2 Interpretation of Animal Model Results
Animal models, no matter how well selected, are still just models. A model,
by definition, is only an approximation of the phenomenon that is desired to be
studied. Care and intelligence should be used in the interpretation and
implementation of results derived from an animal model for applications to humans.
1.7.3 Selection of an Animal Model
Care must be taken in the selection of the model, because animal physiology
is often different from that of humans, and the effect that is desired to be studied in
humans may be very different in animals. A simple example of this would be the
attempted use of a reptile model for the study of body temperature change in humans
with cold exposure. A reptile does not have a steady internal body temperature, and
has no regulation mechanism, but humans do, so the reptile model would be unable to
model the human phenomenon, because the mechanism desired for study, does not
exist in the model. To be able to select an effective animal model, knowledge of the
phenomenon in humans and the similar phenomenon in animals must be known, or
some knowledge of the mechanism must be known before the experiment can begin.
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Many studies (biochemical and radiodensiometric) have established that
disuse (immobilaztion, paralysis, and weightlessness), and sex hormone deficiency
causes loss in bone mass (Nestle, 2000; Li, 2001; Yang, 1997; Bain and Rubin, 1990;
Smith and Gillian, 1989; Weinreb, et al., 1989; Wronski et al., 1985; Okumura, et al.,
1986; Schoutens, et al, 1984; Saville, 1969; Muhlbaur, et al 1971).
This study used a sex hormone deficient rabbit model that has been shown to
have the desired biological effects on bone that we wish to study, and the 140 day
duration will allow for two full remodeling cycles, which should allow sufficient time
for the observation of change in fragility, if any, with treatment (Mashiba et al.,
2001).
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CHAPTER 2: FRACTURE TOUGHNESS OF BONE
2.1 Bone as an Engineering Material
Bone is an anisotropic material. The material properties depend on several
factors, such as microstructure (Wagner and Weiner, 1992), density (Behiri and
Bonfield, 1984) and orientation (Pope and Outwater, 1974). Correlations between
strength and fracture toughness, one cannot be predicted from the other (Zioupos and
Currey, 1998).
Bone is often thought of as a composite material. A composite is a material
that has at least two distinct materials or phases (matrix and fiber), and bone is often
thought of in this way, because of the nature of the collagen fibers and minerals.
2.2 Introduction to Linear Elastic Fracture Mechanics (LEFM)
Linear Elastic Fracture Mechanics (LEFM) is assumed valid when the plastic
deformation around the crack tip is small compared to the crack length. When this
condition is violated other methods of analysis such as Elastic Plastic Fracture
Mechanics (EPFM). The test specimen must be designed such that this condition is
met for the material being tested.
Fracture toughness is the measure of a damaged material to resist the
propagation of the crack or damage. This is a good measure for bone, because bone
is damaged by its very nature. This is because of the modeling and remodeling cycles
that cause the lacunar structure, which would be called damage in an engineering
structure. Fracture toughness analysis is conducted using an energy balance approach
or a stress field analysis.
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2.2.2 Energy Balance Approach
The key idea to this approach is that a crack will only grow when there is
sufficient potential energy in the material to overcome the resitance of the material.
As the crack extends there is a decrease in elastic strain energy within the stressed
specimen. The total energy, U, can be described by the following equation:

U = U o +U a + Uγ − F
where Uo is the elastic energy of the loaded uncracked plate, Ua is the internal strain
energy, Uγ is the elastic surface energy, and F is the work done by the external force.
2.2.3 Stress Analysis Approach
This technique, as the name implies, analysizes the stresses in the vicinity of
the crack tip. The maximum stress intensity at the crack tip before crack extension is
the critical stress intensity factor and is denoted by Kc. The stress ahead of the crack
tip in linear elastic materials is described by:

σ ij =

K
f ij (θ )
2πr

where r is the radial distance from the crack tip and θ is the polar direction from the
crack tip. As r increases to r >> 0, the stress becomes zero.
For thicknesses smaller than 3 mm a linear relationship exists between KIC2
and GIC (Wright and Hayes, 1977; Behiri and Bonfield, 1984). KIC and GIC are
generally considered to be equivalent measures of fracture toughness, KIC reaches a
constant value for certain thicknesses, but GIC continues to decrease with increasing
thickness for the bovine tibia (Norman, et al 1995b). The lack of a shown constant
value for GIC in cortical bone with thickness makes KIC an attractive test parameter;
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even though GIC has been predicted to be a better indicator of composite, such as
bone, fracture toughness (Grootenboer and Weersink, 1982).
2.3 Introduction to Fracture Toughness Testing (Stress Analysis Approach)
Fracture toughness has become a very important field in engineering. This
field analyzes materials and structures that are already built, and may not have the
ideal material and structural properties that were present when the structure was first
made. A classic example of fracture toughness analysis is the cracked bridge
problem.
A mechanics of materials approach to the analysis of a flaw is to just model
the material as if it were a perfect material, only weakened by some factor. This is
often a good means of modeling, but a danger inherent in cracks is the potential for
the crack to propagate suddenly and uncontrollably, particularly in brittle materials.
Bone by its very nature, from an engineering standpoint, fits the concept of
being a “damaged” material, because the bone is under a constant state of crack
growth and crack repair.
2.3.1 Modes of Testing
There are three modes of loading, which can be applied singly or in
combination to a body, labeled as modes I, II, and III. Mode I is also known as the
opening mode, in which the crack propagates perpendicular to the applied load.
Mode II is the sliding of one of the crack faces with respect to the other, which is why
it is also known as the shear mode. Mode III is also known as the tearing mode, since
is it similar to the tearing of a piece of paper, and is valuable in the measure of
resistance to out-of-plane shear.
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Mode I fracture toughness testing was the focus of this paper, so more detail
will be given for this type.
There are several orientations that the fracture toughness specimen can be
taken from the specimen. The various orientations are significant in bone, because of
the linearly isotropic material properties of bone. Behiri and Bonfield (1989) using
bovine bone, and Norman, et al (1996) using human bone showed that the crack will
propagate in the longitudinal direction regardless of the loading direction, which
would imply that bone is less tough in the longitudinal direction, which is consistent
with the composite theory of bone and the orientation of the collagen fibers. The
shear cracks has been observed to propagate between the lamellae, along the cement
lines (Saha, 1977; Vashisth, 1997).
2.3.2 Fracture Mechanics of Composite Materials
Fracture in composite materials is different than in an isotropic material,
where the crack will only grow in size. The fracture of composite materials depends
on the properties of the phases and also the interface between the phases. The
fracture can depend on any of these properties, or a combination of all of them.
2.3.3 Specimen Dimensions
The specimen dimensions are very important, since K is thickness dependent,
with K increasing as the thickness increases, to a maximum and then begins to
decrease with increasing thickness. The limiting value of K at plain strain is a
property independent of size and geometry, which is known as KC, also known as
fracture toughness or stress intensity factor. KC uniquely characterizes the crack tip
conditions, as long as the plastic zone is small.
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KIC has been shown to linearly increase with increasing width in compact
tension specimens machined from bovine bone (Bonfield, et al 1985). KIC has also
been found to be independent of thickness for 1.85 mm – 3 mm (Wright and Hayes,
1977) and for 0.5 mm – 2 mm (Behiri and Bonfield, 1984), which allows for some
margin of error in machining of specimens. Although it KIC is independent of the
specimen thickness at certain ranges, plain strain is achieved at the larger thicknesses,
so bone fracture toughness values from the literature, and this paper, can not
generally be represented by plain strain fracture toughness. Norman, et al in 1991
determined that the minimum thickness for a 17.5 mm x 16.8 mm CT specimen to
achieve plane strain conditions for bovine bone was 7 mm, which is difficult to
achieve in most animals and in humans.
The compact tension specimen must meet some dimensional requirements to
have a valid test. According to ASTM E 399 recommendations, the dimensions
should meet the following:

0 . 45 ≤ a / W ≤ 0 . 55
 KQ
B , (W − a ) ≥ 2 . 5 
 σ YS





2

The CT specimens were machined using the same proportions as those
described by Norman, et al. (1996), with B equal to 0.5 mm and W being
approximately 5 mm, and the crack length a is 2 mm long.
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W
a
1.2 W

1.25 W

Figure 2.3.3-1: Schematic of the Compact Tension (CT) specimen.
Although fracture toughness testing for bone may not satisfy the reguirous
requirements laid out above for plain strain fracture toughness, fracture toughness is
still useful in comparisons within groups.
2.3.4 Stress Analysis Calculations
There are three modes of testing, therefore there are three stress intensity
values that depend on the type of testing employed. These three stress intensity
values are denoted in the literature as Kk, where k is a I, II, or III depending on the
mode of testing used.
The stress intensity value, K, is the fracture toughness parameter of the
stresses around the crack tip. The testing used in this experiment was mode I and the
mode I stress intensity factor can be calculated from equation 1.

PQ

a
f 
(1)
B W W 
Where a is the length of the chevron from the crack tip to a line connecting the two
K IC =

holes, W is the linear length from the holes to the end of the specimen past the tip, B
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is the thickness of the specimen, f(a/W) is a dimensionless geometric property called
the shape factor. The shape factor can be calculated using equation 2.
a
a
f   = 29.6 
W 
W 

0.5

a
− 185.5 
W 

1.5

a
+ 655.7 
W 

2.5

a
− 1017 
W 

3.5

a
+ 638.9 
W 

4.5

(2)

The load PQ is found from the analysis of the test results. The results are plotted on a
graph of load versus displacement, as shown in figure 2.3.4-1.

5% Secant Line

Load

Test Data

Displacement

Figure 2.3.4-1: Fracture toughness test results plots with 5% secant line plotted.
The slope is found for the elastic portion, linear portion, of the graph. A 5% secant
line is drawn from the linear portion of the graph, to insure that the plane strain
condition is maintained. After the line is drawn, the intersection between the line and
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the test results is the P5 value, which if it meets the following conditions is used as PQ
in the equation above. PQ must meet the condition of:

P max ≤ 1 . 10 PQ
This condition can be seen in figure 2.3.4-2, when the 5% secant line is plotted.

Figure 2.3.4-2: Fracture toughness test result analysis, showing the three possible
outcomes of the 5% secant line being plotted on the graph (Anderson, 1991).
If P5 occurs after Pmax , as in Type III in figure 2.3.4-2, Pmax is used to satisfy the
condition of stress at the initiation of the crack, and using this P5 would underestimate
the fracture toughness of the material. If the test data shows a pronounced spike, as
in Type II in figure 2.3.4-2, and then a decrease before continued increase, the value
as the top of this spike is used as the PQ value, since the equation is concerned with
the initiation of the crack, which would has occurred around this point, and not at the
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point found by Pmax or the 5% secant line. If P5 occurs as shown in Type I in figure
2.3.4-2, than this value is used as PQ
Another property of fracture toughness testing that is analyzed is the
compliance, which is the inverse of the slope of the linear portion of the stress versus
displacement graph of the test values.
2.4 Specimen Orientation
Bone properties are directional dependent, so the orientation must be given
special consideration. ASTM defines the crack direction as shown in figure 2.4-1.

Figure 2.4-1: Crack direction definition for cylindrical geometries (ASTM, 1989;
Anderson, 1991).
Some literature values do not define the directions as shown in figure 2.4-1, so care
must be used in deciphering the type of test used. Using the above definition, the
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long axis would correspond to the longitudinal direction or L in the above figure.
Fracture toughness specimens in this study were from a C-L orientation.
Cracks in ungrooved specimens tend to propogate in the longitudinal direction
reguarless of the loading direction (Behiri and Bonfield, 1989), which would imply
that bone is less tough in this direction. To overcome the tendency for the crack to
propagate in the longitudinal direction, grooved speciemens were introduced to direct
the crack. Experiments using grooved bovine tensile speciemens showed that KIC
was the greatest transverse to the bone’s long axis followed by cracks 15o to the long
axis with KIC for the longitudinal (0o from the long axis) being the lowest (Behiri and
Bonfield, 1989).
2.5 Tibial Fracture Toughness Values from the Literature
The fracture toughness of bone has been studied by several researchers (Table 2.4-1),
but the particular effects of treatment on the fracture toughness are not known, which is the
purpose of this study.
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Table 2.4-1: Stress Concentration Factors for the Literature for the Tibia (Adapted from
Yeni, 1998)
Author(s)
Bonfield & Datta
(1974)

Species

Experiment

Measurement

Direction

Loading Rate

Bovine

Center Notched Shock Tube

Kc=0.23

Longitudinal

~ 7 s^-1

Bonfield & Datta
(1976)

Bovine

Single-edge Notched

Kc=2.2 - 4.6

Transverse

3e-3 s^-1

Behiri & Bonfield
(1980)

Bovine

CT

Kc = 4.46 - 5.38

Longitudinal

0.0102 - 1.02
mm/min

Behiri & Bonfield
(1982)

Bovine

CT

Kc = 3.3 - 5.7

Longitudinal

Behiri & Bonfield
(1984)

Bovine

CT

Kc = 2.8 - 6.3

Longitudinal

0.01 - 50
mm/min

Human

CT

Kc = 2.1 - 4.7

Longitudinal

0.504e-3
mm/min

Canine

CT

Kc = 3.2 - 6.5

Longitudinal

0.0102
mm/min

Moyle & Gavens
(1986)

Bovine

Single-edge Notched

Kc = 11.2

Transverse

0.45 mm/min

Behiri & Bonfield
(1989)

Bovine

CT (grooved)

Kc = 3.2

Longitudinal

0.0198
mm/min

Norman et al
(1991)

Human

CT

Kc = 4.48

Longitudinal

0.5 mm/min

Norman et al
(1991)

Human

CT (corrected for 7 mm
thickness)

Kc = 3.68

Longitudinal

0.5 mm/min

Norman et al
(1992)

Bovine

CT

Kc = 5.3 - 9.4

Longitudinal

0.5 mm/min

Norman et al
(1992)

Bovine

CT (grooved)

Kc = 5.2 - 9.3

Longitudinal

0.5 mm/min

Valishth et al
(1994)

Bovine

CT

Kc = 4 - 7.6

Longitudinal

0.5 mm/min

Valishth et al
(1994)

Human

CT

Kc = 1.6 - 2.5

Longitudinal

0.5 mm/min

Norman et al
(1995)

Bovine

CT

Kc = 4.68 - 6.73

Longitudinal

2.6 mm/min

Norman et al
(1995b)

Human

CT

Kc = 4.05 - 4.32

Longitudinal

2.6 mm/min

Feng & Salzmann
(199)

Bovine

CT

Kc = 2.55

Longitudinal

0.2 mm/min

Norman et al
(1996)

Human

CT

Kc = 2.12

Longitudinal

0.2 mm/min

Bonfield et al.
(1985)
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CHAPTER 3: FEMORAL NECK TESTING
3.1 Introduction to Femoral Neck Testing
As it has been mentioned earlier, femoral neck fractures are a common type of
osteoporotic fracture. Femoral neck testing is a test of the femoral head and neck
structure, namely the femoral neck’s ability carry load. This testing was done to find
the ultimate strength of the femoral neck structure, and to see if the treatment had an
effect on the load carrying ability of the femoral neck, which would ultimately relate
to the femoral neck’s ability to resist fracture.
The geometry of the femoral neck of rabbits differs from the human femoral
neck that these test are often performed, but the rational of being able to test a
structure is the same, even if the structure is different.
3.2 Rational for Testing
The tests were performed to gain insight into structural changes of the bone
and its ability to carry load, which gives another area to correlate the fracture
toughness data. The femur is a heavily loaded region and is commonly involved in
osteoporotic fractures, and is second in prevalence after vertebral compression
fractures.
The femoral neck is a common area for fracture in humans because of the
relatively small size, low mass, and heavy loads received under normal activities.
The rabbit femur is unique in the large femoral neck region that goes lower on the
shaft relative to size than the human counterpart, which makes the fracture behavior
unique. The unique fracture properties do not make the femur untestable, since this
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characteristic is shared by all of the test specimens, and a difference can be found
between treatment groups.
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CHAPTER 4 HISTOMORPHOMETRY OF BONE
4.1 Introduction to Histomorphometry
Histomorphometry is the term used to describe the measurement and
quantification of microscopic specimens.
4.1.1 Example of use of the Lexicon
The abbreviations are used in the order of the words in the measurement
description, such as single pore area, which would be abbreviated as s.Po.Ar. The use
of abbreviations was standardized, but was not overly suggested by Parfitt (1987)
with the purpose of standardizing abbreviations when used to report data. The
abbreviations will be used in this paper to report measurements, because of their
compact size and the ease to which they lend themselves to the potential writing of
data analysis computer programs for post processing of the data.
4.1.2 Example of Measures
There are different types of histomorphometric measures. These measures
can be divided in a few categories namely: static and dynamic, and primary and
secondary (calculated) measures.
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Table 4.1.1: Abbreviations and Symbols of Terms Used in Bone Histomorphometry (Parfitt,
1987)
A
Ab
Ac
Aj
Ar
a
B
BMU
Ca
Cd
Cn
Ct
d
E
EX
F
Fb
Fr
f
G
H
Hp
Ht
Hz
I
Ic
Il
In
Ir
i
L
Lc
Le
Lm
Ln
Lo
l
M
Me
Ml

m
N
n
O
Ob
Oc
On
Ot
P
Pm
Po
Ps
Pt
Q
R
Rd
Rf
Rm
Rs
S
Sa
Se
Sn
St
s
Tb
Th
Tt
t
U
V
Vd
Vk
Vt
W
Wi
Wo
Z

Apposition(al)
Absolute
Activation
Adjusted
Area (2D)
Activ(e)(ity)
Bone
Basic Multicellular Unit
Canal(icula)(r)
Corrected
Cancellous
Cortical
Double
Ero(ded)(sion)
External
Formation
Fibro(sis)(us)
Front
Frequency
Grow(th)(ing)
Haversian
Hypertrophic
Height
Horizontal
Interface (3D)
Intercept
Initial
Internal
Inter
Intersection
Label(led)
Lacuna(r)
Length
Lamella(r)
Line
Longitudinal
lag
Mineral(iz)(ing)(ation)
Medullary
Modeling
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Maturation
Number of profiles or structures
Number of sampling units
Osteoid
Osteoblast(ic)
Osteoclast(ic)
Osteon(al)
Osteocyt(e)(ic)
Period
Perimeter (2D)
Por(e)(ous)(osity)
Periost(eal)(eum)
Point
Quiescent
Rate
Radi(al)(us)
Referen(ce)(t)
Remodeling
Resorption
Surface (3D)
Sample
Section
Spongiosa
Structur(e)(al)
Single
Trabecula(r)
Thickness (3D)
Total
Time
Unit
Volume (3D)
Void
Volkmanns
Vertical
Wall
Width
Woven
Zone

4.3 Static Histomorphometry
Static histomorphometry is the microscopic measure of surfaces and
structures. The measures are called static, because the structures and surfaces of
bone, are no longer living, embedded in plastic, and are unchanging.
Most measures are in terms of percent of the total area, which is done for a
few reasons. Measures of length, when dealing with such small sizes, are difficult.
The surfaces and areas of interest are irregular in shape, so the use of linear measures
to then extrapolate an area is difficult. Image analysis software that easily allows the
measure of the percent of the total area occupied by a unique region.

Total Area (TtAr)
The total area is exactly that, the total area of the image. When a picture is
analyzed, the measures are usually in terms of percentage of a larger area, and this is
the most basic one.

Medullary Area
The medullary area is the area enclosed by the cortical bone. For illustrative
purpose, a long bone (i.e. femur, or tibia) can be thought of as hollow pipes. The
medullary area would then be the area found from internal diameter (ID). The
medullary area is often thought of as a percentage of the total area from the equation:
MeAr (%) = MeAr/TtAr

Cortical Bone Area (CtAr)
The cortical bone area is defined as the area that is composed of cortical bone,
and is usually expressed as a percentage of the total bone area by the equation.
CtAr = TtAr – MeAr-Other Area
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Other Area is all the area that may lie on the outside of the cortical bone that is not
part of the medullary area, and is not bone area, such as any area in the field that lies
outside of the cortex.
The cortical bone area though is often reported as a percentage of the total
area, from the equation:
CtAr (%) = CtAr/TtAr = 1-MeAr/TtAr = 1 – MeAr (%)

Osteon Area (OnAr)
The osteon area is expressed as the percentage of the total area that is
composed of osteons, or more precisely the percentage of the bone area that is
enclosed within cement lines, which are the boundaries of the osteon. The area of
each osteon is summed and then divided by the total cortical bone area (CtAr), or
from the equation:
OnAr = TOnAr/ CtAr

Porosity (Po)
The porosity of the bone or the percentage of the total bone that is porous is
found by finding the areas of the haversian, and volkmann canals, any other spaces
that are present in the cortical bone, and the total area of the cortical bone. The
porosity (Po) can then be found by the equation:
Po =

Hn.Cn. Ar + V .Cn. Ar + Pr .V . Ar
Tt. Ar

Osteon Number (OnN)
The osteon number is simply the number of osteons present in the bone
specimen, which is measured by using analysis software to count the number of
osteons identified by the user. This parameter gives an idea as to the
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resorption/formation activity present in the bone, but does not give areas of any sort.
If two osteons and haversian canals are merged together, as shown in figure 4.3-1,
they are counted as two osteons, because they are two independent osteons.

Figure 4.3-1: Merged osteons (Wang, 1995).
If two osteons are merged by a Volkmann’s canal, these are also counted as two,
because they are independent osteons.

Figure 4.3-2: Osteons connected by a Volkmann’s canal (Wang, 1995).
If the Haversian canals are separate, but the osteons are merged together, each osteon
is counted, because each is still an independent system.
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Figure 4.3-3: Merged osteons with independent Haversian canals (Wang, 1995).
When images are made, some osteons may only be partially in the field as shown in
figure 4.3-4. The partial osteons are counted as well.

Figure 4.3-4: Osteon fragment cut by edge of the field (Wang, 1995).
If an osteon fragment does not have a clear haversian canal (figure 4.3-5), but does
have a clear cement line, the fragment is also counted, because it has important
mechanical properties similar to those of osteons with Haversian canals.

Figure 4.3-5: Osteon fragment with a clear cement line (Wang, 1995).
Occassionally an osteon will appear to have a double cement line, which could be
caused by the specimen being sectioned oblique to the face or to a small remodeling
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event. The osteon, similar to the schematic in figure 4.3-6, is counted as one, and the
outer cement line is used for measurement purposes.

Figure 4.3-6: Osteon, which appears to have two cement lines (Wang, 1995).

Osteon Density (OnD)
Osteon density is an index of the number of osteons per unit area, which can
be found from the equation.
OnD = OnN/CtAr

Osteoid Area (OAr)
The osteoid area is the area of the bone occupied by osteoids, but this quantity
like most bone quantities is given as a percentage of the cortical bone area from the
equation.
OAr = OAr/CtAr
4.4 Compositional Analysis (R Cain et al, 2003)
The mineral and organic content of bone can be found from a drying
procedure as follows:
1. The dimensions of the specimen were measured using calipers, and the
volume (V) of the cylinder was calculated.
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2. The specimens were hydrated overnight in water, lightly blotted dry,
and then the wet weight (WW) was found.
3. The specimen was then defatted by soaking in acetone in a vacuum
oven (20 psi; 60 oC) for 24 hours.
4. The specimen was brought back to room temparature in a dessicator (1
hour). The specimen was then weighed. This was repeated until a
constant mass was found, which is the dry weight (DW).
5. The specimens were then placed in a crucible in a muffle oven at 600
o

C for 24 hours. The specimen’s ash weight (AW) was then found.

6. The following parameters were then calculated:
Weight Density = WW/V
Dry Density = DW/V
%Mineral, %Min = AW/DW * 100
%Organic (dry) = (DW – AW)/DW *100
%ASH = AW/DW * 100
%Organic (wet) = (DW – AW)/WW *100
% Water = (WW-DW)/WW * 100
The %Ash can be thought of as the apparent mineral content, and the
%Mineral is the material mineral content and is independent of porosity. The
%Organic (dry) is the organic content and is independent of porosity, and the
%Organic (wet) is the apparent organic content of the bone.
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CHAPTER 5 ANIMAL CARE AND EXPERIMENTAL PROCEDURE
5.1 Introduction
The experiment used a total of twenty-eight New Zealand White (NZW)
rabbits (Covance, Denver, PA), which were divided into three trial groups and four
treatment groups.

Group I (N = 6)
Group I consisted of eight rabbits. Four of these rabbits were ovarectomized
and four of them were sexually normal. The purpose of this group was to illustrate
the difference between the overectomized and normal groups, and add validity to the
rabbit Ovx model.

Group II (N = 8)
Group II consisted of eight rabbits, all of which had received ovarectomies.
Four of the animals received risidronate injections of 5 µg/ml/kg three days per week
(M, W, and F), meaning animals in this group that received Residronate (Actonel,
Proctor and Gamble) received an injection of a solution of a concentration of 5 µg/ml
and then given a dose of one ml per kg of body weight. The remaining four rabbits
received saline injections equal to 1 ml/kg.

Group III (N = 16)
This group consisted of all four treatment methods (Normal, Ovx-NaCl, OvxRis, Ovx), as described previously with four animals per treatment method.
A more visually pleasing representation of the division of specimens can be
seen in table 5.1-1.
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Table 5.1-1: Animal Treatment and Group Distribution Table
Normal (No Injection)
Group I: n = 5
Group III: n = 4
Ovx (Residronate Injection)
Group II: n = 4
Group III: n = 4

Ovx (No Injection)
Group I: n = 4
Group III: n = 4
Ovx (Saline Injection)
Group II: n = 4
Group III: n = 4

5.2: Animal Care Introduction
Animals deserve a level of respect and consideration when an experiment is
designed. There are many moral and legal issues that must be addressed before the
use of animals should be considered.
Animals should not be used in experiments unless the data is simply
unavailable from any other model. If the data can also be derived by a computer
model, even if the accuracy is lower than an in vivo model, it should be strongly
considered.
From a legal point-of-view, the use of animals is strongly regulated by the
United States Government under the authority of the Department of Human Services.
All of the animals in the study were housed by the West Virginia University
Office of Laboratory Animal Research at the Robert C. Byrd Health Sciences Center
Morgantown, WV. The animal quarters officials took care of feeding, watering, and
cleaning duties necessitated by the use of animals.
The experimental procedure received Animal Care and Use Committee
(ACUC) approval (# 01-1102).
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5.3: Animal Injection Procedure
All injections were given subcutaneous on the dorsal side of the animal. The
animal was placed on a flat surface outside of its cage, and the skin of the posterior
dorsal region was pinched up. The needle was then inserted into the skin horizontally
along the length of the pinch. The plunger was then slowly pressed forward, to allow
for the maximum comfort of the animal, since a relatively large volume of fluid is
being introduced to the animal. The area was then examined by lightly rubbing the
hand over the dorsal area in a petting motion. The petting has a two pronged purpose:
it allows for the checking of dosing, since if the injection is not fully successful, the
liquid will be stuck in the fur and will not be readily visible, and the stroking of the
animal helps to comfort and sooth the animal, that is stressed by the injection
procedure.
5.4: Animal Sacrifice Procedure
The animals were brought from the animal housing area to the operating
room, in which the dissections were to take place. The animal is anesthetized using
an injection of Ketamine (Ketajet, 100mg/ml, Phoenix Scientific, St. Lois, MO) and
Xylene (Xylajet, 20 mg/ml, Phoenix Scientific, St. Lois, MO) in a 30 ml to 10 ml
mixture. Once the animal is asleep, an injection 30 ml of Sleep Away (Fort Dodge
Laboratories, Fort Dodge, IA) is injected directly into the cardiac muscle, which leads
to almost instantaneous cardiac arrest.
5.5: Animal Dissection
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Once the animal is confirmed dead, the hind limbs are dissected and the
femurs and tibias are removed and cleaned. The bones were wrapped in saline
soaked gauze and placed in labeled bags. The specimens were then placed in a freezer
(-20 oC), until the specimens were used in mechanical testing.
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CHAPTER 6: SPECIMEN PREPARATION, MACHINING, AND ANALYSIS
6.1 Bone Selection and Bone Availability
The tibia was selected for the preparation of the fracture toughness specimens,
because of the relatively flat aspects of the bone on the proximal end, which allows
for the machining of the compact fracture toughness specimens.
6.2 Specimen Preparation and Storage
When machining was going to be performed on the bones, only the number
expected to be machined that day were removed from the freezer in the morning to
defrost at room temperature. Hydration was maintained as well as possible during the
machining process using normal saline to avoid drying out of the specimens.
After the machining process, the specimens were wrapped in saline soaked
gauze and then placed in a labeled plastic bag; after which, the bones were placed in
the refrigerator (4 oC) for no more than a few days until testing took place.
Before mechanical tests were performed, the bone specimens were removed
from the refrigerator and allowed to return to room temperature, before testing was to
begin. Hydration was maintained throughout the testing process using normal saline.
6.3 Fracture Toughness Machining
All specimens were removed from a flat lateral aspect of the proximal tibia
adjacent to the fibula as shown in figure 6.3-2. This area provided the flattest and
thickest area of cortical bone from which to extract a fracture toughness specimen.
The proximal end was removed by cutting it off perpendicular to the axis of
the bone using a band saw at a location low enough on the shaft of the bone, such that
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there was sufficient cortical bone for the machining of the specimens. Using a
jeweler’s saw with a fine cutting blade, a slab was then removed along the selected
flat aspect down the shaft of the bone, care was taken to ensure that a minimum
amount of the other faces were removed, while still allowing the removal of the entire
aspect down to approximately the midpoint of the shaft.
The slab once removed was ground flat using wet 180# sandpaper, and then
placed on a specially designed fixture designed by Vincent Kish and myself (figure
6.3.1) and secured using the set screws.

6.8 mm

17.1 mm

Figure 6.3.1: Machining Fixture for Milling and Drilling Processes
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W
a
1.2 W

1.25 W

Figure 6.3-2: Fracture Toughness Specimen Location and Dimensions (Adapted from
Wingerd, 1985 with CT specimen added)
The slab once secure in the fixture (Figure 5.3-1) was placed in the clamp in
the vertical milling machine, and the center portion between the two clamps was
milled to the desired thickness of 0.5 mm using a 3/16” milling bit running at 2300
RPM.
Once the center portion was milled to the correct thickness (0.5 mm), the
holes for the fracture toughness specimen were drilled by putting a 1 mm diameter bit
into the head of the milling machine and using as a press at 270 RPM. The hole
placement was found by using a Mill Mate (Bridgeport, Bridgeport, CT) digital
device that is connected to the bed of the mill/press and reads distance change on the
horizontal plane.
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Once the holes were drilled into the specimen, it was removed from the
fixture, and the measurements for the dimensions were made using the center of the
holes as a reference point.
Once the measurements were transferred in pencil to the specimen, it was
removed and cut to the proper length using a Buhler Low Speed Saw.
Once the specimen was the proper length, the crack was cut into the specimen
on the Low Speed Saw (Buehler, Evanston, IL) using a blade of 10.2 cm diameter and
a thickness of 0.3 mm.
Prior to testing, the precrack was made at the end of the crack using a new flat
razor blade.

Figure 6.3-3: Making of the precrack (Yeni, 1998).
6.4 Histomorphometric Preparation
Complete cross sections were cut from the tibial shaft below the area used for
the fracture toughness machining. A bulk section was cut from the middle of the
shaft. The bulk section was embedded in plastic. After the embedding process, at
least two 80 mm sections were cut using a diamond wire saw (Delaware Diamond

- 51 -

Knives, Wilmington, DE). At least one section was stained using H&E (Appendix
A); the section after staining was mounted on a microscope slide with Permount
(Fisher Scientific, Fairlawn, NJ) and a cover slip was applied. At least one other
section was mounted on a slide unstained using Fleoromount-G (Southern
Biotechnology Associates Inc., Birmingham, AL) for dynamic histomorphometry.
6.5 Femoral Neck Fracture Testing
The femoral neck was tested by cutting the femur perpendicular to the axis at
the mid-shaft, taking care to insure that it was below the obvious neck structure. The
bones were then “potted” or fixed in a metal tube using Duz-All Self Cure Acrylic
Dental Cement from Coralite Dental Products (Skokie, IL). The structure of the
femoral neck was then tested on the MTS (MTS Corp., Minneapolis, MN).

Figure 6.5-1: Femoral neck testing configuration with the arrow indicating the load.
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6.6 Bone Mineral Density Testing
The bone mineral density of the femurs for group II were tested at the Ohio
State Musculoskeletal Research Center by Dr. John Landell. The bones were shipped
to the OSU lab by FedEx in a Styrofoam box with dry ice. The bones upon receipt at
OSU were kept frozen and then tested using DXA. After the analysis the bones were
shipped back to Morgantown, WV, using the same box with dry ice.
6.7 Histomorphometric Analysis
Four fields were selected at random and an image was captured using the 20x
objective on the microscope (Olympus BH-2, Japan). The images were then analyzed
using Scion Image version Beta 4.02 (Scion Corporation) and the results were
exported as a text file. The text file was then opened in Microsoft Excel version
9.0.2720 for analysis. After the analysis, statistical analysis was performed using
JMP (version 3.2.1, SAS Institute, Inc).
6.8 Statistical Methods
Statistical comparisons between groups and line fitting for the data was
performed in JMP (version 3.2.1, SAS Institute, Inc). Significance was tested using
ANOVA, student t-test, and Tukey-Kramer HSD. The confidence interval was set at
95% (p<0.05).
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CHAPTER 7: RESULTS
7.1 Introduction
The data in this investigation was for determining the bone quality of bone,
and the effects of estrogen deficiency and bisphosphonate treatment on the quality of
bone. To get a clearer picture as to the effects of the drug treatment and estrogen
deficiency on the mechanical properties a variety of tests were employed. The most
important for our study was fracture toughness, and the other tests and measures were
done to explain the difference or lack of differences found from this test.
7.2 Fracture Toughness Results (Stress Intensity Factor)
Fracture toughness testing was performed for all three groups. The stress
intensity factors were calculated as described earlier, and the results in each group
were compared, within the same experimental group and all groups.
Group I:
The fracture toughness of Group I was performed using a different machining
technique than that employed in groups II and III. During this test many of the
specimens broke during the machining process, particularly the Ovx bones, which
were seemingly too brittle to go through the machining process without breakage.
The difference between the treatment groups was significant, but the Ovx only had
one specimen in the test. The results for the group can be seen in table 7.2-1 and
figure 7.2-1.
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Table 7.2-1: Fracture Toughness Test Data for Group I.
Kc
W
(mm) a (mm) Fc (N) B (mm) a/W f(a/W) (N/mm^3/2) Treatment
6.80
2.40
5.76
0.60
0.35 6.59
24.27
Ovx

Specimen
977
981a
981b
982
983
Normal Avg.
Normal SD

6.33
6.50
5.58
5.80
6.05
0.43

2.00
2.20
2.40
2.50
2.28
0.22

12.84
11.98
9.25
4.57
9.66
3.72

0.81
0.80
0.63
0.50
0.69
0.15

0.32
0.34
0.43
0.43
0.38
0.06

6.08
6.38
7.96
7.98
7.10
1.01

38.32
37.47
49.47
30.32
38.90
7.91

Norm
Norm
Norm
Norm

45

40

35

30

20

15

Ovx

25

Normal

Stress Intensity Factor (N/mm^1.5)

50

10

5

0

Figure 7.2-1: Stress intensity factor results for Group I (The average value for
Normal is 38.9±7.91 and the only value for Ovx was 24.27).
Group II:
In Group II, the stress intensity factors were not significantly different
between Ovx and Ovx-Ris groups, which can be see in table 7.2-2 and figure 7.2-2.
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Table 7.2-2: Fracture toughness test values for Group II

NaCl
NaCl
NaCl

20.00
22.00
23.00
Average
SD

Mass
(kg)
4.40
5.10
4.80
4.77
0.35

Ris
Ris
Ris
Ris

21.00
24.00
25.00
26.00
Average
SD

4.80
6.00
4.30
3.50
4.65
1.05

Treatment Number

a/W

f(a/W)

11.68
14.34
13.67
13.23
1.39

a
W
T (mm)
(mm) (mm)
1.37 6.85
0.77
1.24 6.07
0.61
1.21 6.84
0.53
1.27 6.59
0.64
0.09 0.45
0.12

0.20
0.20
0.18
0.19
0.01

5.23
5.24
5.21
5.23
0.02

Kc
(N/mm^3/2)
30.30
49.99
51.34
43.88
11.78

18.44
8.80
10.92
12.15
12.58
4.15

1.18
1.40
1.18
1.44
1.30
0.14

0.17
0.21
0.18
0.22
0.19
0.03

5.21
5.26
5.21
5.30
5.24
0.04

68.22
36.83
66.51
45.10
54.16
15.63

Fc (N)

7.06
6.58
6.71
6.49
6.71
0.25

0.53
0.49
0.33
0.56
0.48
0.10

140

120

Kc (N/mm^3/2)

100

80

60

Ovx-Ris

20

Ovx-NaCl

40

0

Figure 7.2-2: Stress intensity factor results for Group II (The average values are
43.88±11.78 N/mm^1.5 for Ovx-NaCl and 54.16±15.63 N/mm^1.5 for the Ovx-Ris
group)
Group III:
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The stress intensity factors for all of the treatment in Group III were
calculated, but none of the groups was significantly different, as can be seen in figure
7.2-3 and table 7.2-3.
Table 7.2-3: Fracture toughness test data for Group III

Normal
Normal
Normal
Normal
Normal
Norma

127
128
129
130
Average
SD

Mass
(kg)
4.91
2.90
5.02
4.85
4.28
1.19

10.07
3.08

1.28
0.86
1.03
1.30
1.06
0.21

4.74
4.64
3.93
3.60
4.44
0.44

0.55
0.63
0.66
0.52
0.61
0.06

0.27
0.19
0.26
0.36
0.24
0.05

5.60
5.21
5.53
6.71
5.45
0.21

Kc
(N/mm^3/2)
61.75
27.10
42.10
0.00
43.65
17.38

NaCl
NaCl
NaCl
NaCl
NaCl
NaCl

138
139
141
142
Average
SD

5.67
4.71
4.55
4.31
4.81
0.60

13.2714
12.3344
6.9785
16.0137
12.15
3.78

1.40
1.17
1.38
1.3
1.31
0.10

4.67
4.32
4.47
5.6
4.77
0.57

0.56
0.79
0.64
0.88
0.72
0.14

0.30
0.27
0.31
0.23
0.28
0.03

5.89
5.61
5.99
5.34
5.71
0.29

64.60
42.10
30.91
41.07
44.67
14.21

Ris
Ris
Ris
Ris
Ris
Ris

131
132
133
136
Average
SD

4.61
4.9
5.45
4.76
4.93
0.37

12.0799
15.7682
9.7627
17.8788
13.87
3.64

1.15
1.06
1.06
1.13
1.10
0.05

4.62
4.9
4.11
4.75
4.60
0.34

0.5
0.67
0.52
0.57
0.57
0.08

0.25
0.22
0.26
0.24
0.24
0.02

5.44
5.27
5.50
5.37
5.40
0.10

61.13
56.08
50.95
77.31
61.37
11.41

Ovx
Ovx
Ovx
Ovx
Ovx
Ovx

134
135
137
140
Average
SD

4.71
4.83
4.6
4.88
4.76
0.126

14.2085
11.7027
13.0379
16.5915
13.89
2.07

1.02
1.29
1.2
1.46
1.24
0.18

4.94
4.73
4.5
4.64
4.70
0.184

0.66
0.57
0.67
0.68
0.65
0.051

0.21
0.27
0.27
0.31
0.27
0.045

5.24
5.62
5.57
6.06
5.63
0.34

50.80
53.07
51.10
68.69
55.91
8.58

Treatment Number

Fc (N)
13.2085
7.0593
9.9543

a (mm) W (mm) B (mm)
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a/W

f(a/W)

80.00
70.00

50.00
40.00

0.00

Ovx

10.00

Ovx-Ris

20.00

Ovx -NaCl

30.00

Normal

Kc (N/mm^3/2)

60.00

Figure 7.2-3: Stress intensity factor results for Group III (The average values were
43.65 ± 17.38 N/mm^1.5 for Normal, 44.67 ± 14.21 N/mm^1.5 for Ovx-NaCl, 61.37
± 11.41 N/mm^1.5 for Ovx-Ris , and 55.91 ± 8.58 N/mm^1.5 for Ovx.)
All Groups
When all of the stress intensity factors from all three groups were put together,
the Ovx-Ris group was found to be significantly different the Normal group, but there
was no other significant difference, as shown in figure 7.2-4, using data from tables
7.2-1, 7.2-2, and 7.2-3.
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Figure 7.2-4: Stress intensity factor results for Groups I, II, and III (The average
values were 40.93 ± 11.77 N/mm^1.5 for Normal, 57.71 ± 22.36 N/mm^1.5 for OvxNaCl, 76.23 ± 26.83 N/mm^1.5 for Ovx-Ris , and 49.58 ± 15.98 N/mm^1.5 for Ovx.)
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7.3 Femoral Neck Testing
Femoral neck testing was performed for all three groups.
Group I:
In Group I, the Ovx group had a significantly higher amount of displacement
from start of loading to fracture (figure 7.3-1 and table 7.3-1), but the load at fracture
was not significantly different (figure 7.3-2 and table 7.3-1).
Table 7.3-1: Femoral Neck Test Results for Group I
Specimen Load (N)
982
983
Average
SD
977
979
Average
SD

-1339.68
-858.275
-1098.98
340.4025
-1183.48
-1037.7
-1110.59
103.0761

Displacement
Treatment
(mm)
-2.4173
Normal
-2.4785
Normal
-2.4479
0.043275
-3.2246
Ovx
-3.4234
Ovx
-3.324
0.140573

0

-1.5

Ovx

Displacement (mm)

-1

Normal

-0.5

-2

-2.5

-3

-3.5

-4
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Figure 7.3-1: Comparison of Displacement at Fracture for Group I (Averages are for Normal
-2.45 ± 0.04 mm and for Ovx -3.32 ± 0.14 mm).
0

Normal

-400

-600

Load (N)

Ovx

-200

-800

-1000

-1200

-1400

-1600

Figure 7.3-2: Graph of Force at Fracture for Group I (Averages are for
Normal –1099 ± 340 N and for Ovx –1111 ± 103 N).
Group II:
The displacement from beginning of load until fracture (figure 7.3-3 and table
7.3-2) and the ultimate load (figure 7.3-4 and table 7.3-2) were not significantly
different for the Ovx-NaCl and Ovx-Ris groups.
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Table 7.3-2: Femoral Neck Test Results for Group II
Force
Specimen (N)
19
-1288.24
20
-932.227
22
-1063.78
23
-1483.79
Average -1192.01
SD
243.8075

Displacement
(mm)
-2.2057
-2.1805
-2.7091
-2.4239
-2.3798
0.245230912

21
24
25
26
27
Average
SD

-3.5199
-1.9057
-1.7817
-1.7472
-2.3099
-2.25288
0.742773143

-1655.16
-1176.6
-949.53
-718.903
-1200.78
-1140.19
347.8593

Treatment
NaCl
NaCl
NaCl
NaCl

Ris
Ris
Ris
Ris
Ris

0

Ovx-Ris

Displacement (mm)

-1

Ovx-NaCl

-0.5

-1.5

-2

-2.5

-3

-3.5

Figure 7.3-3: Femoral Head Displacement at Fracture for Group II (The average values were
–2.38 ± 0.25 mm for Ovx-NaCl and –2.25 ± 0.74 mm.)

- 62 -

0

Force (N)

-600

Ovx - Ris

-400

Ovx-NaCL

-200

-800

-1000

-1200

-1400

-1600

Figure 7.3-4: Femoral Head Force at Fracture for Group II (The average values were –
1192.01 ± 243.8 N for Ovx-NaCl and –1140 ± 347.9 N.)
Group III:
The Ovx group had no significant differences in load (figure 7.3-5) or
displacement (figure 7.3-6), this is also shown in table 7.3-3.
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Table 7.3-3: Femoral neck test data for Group III

127
128
129
130
Average
SD

Displacement
Treatment
(mm)
1082.5
-2.89
Normal
792.9
-4.09
Normal
1345.83
-3.01
Normal
942.7
-2.84
Normal
1041.0
-3.21
235.2
0.59

131
132
133
136
Average
SD

1080.132
1116.16
1262.88
890.5103
1087.421
153.2304

-3.24
-1.59
-2.72
-3.27
-2.71
0.78

Ris
Ris
Ris
Ris

134
135
137
140
Average
SD

1084.635
1638.568
1289.901
1120.427
1283.383
253.1495

-3.23
-3.04
-2.48
-3.07
-2.95
0.33

Ovx
Ovx
Ovx
Ovx

138
139
141
142
Average
SD

1214.3
1030.8
937. 7
1155.5
1084. 6
124. 3

-2.46
-2.59
-3.14
-3.12
-2.83
0.36

NaCl
NaCl
NaCl
NaCl

Specimen Load (N)
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Figure 7.3-5: Load at Fracture of Femoral Neck for Group III (The average values
were 1041.0 ± 235.2 N for Normal, 1283.4 ± 253.1 N for Ovx, 1084.6 ± 124.3 N
Ovx-NaCl, and 1087.4 ± 153.2 N for Ovx-Ris.)
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Figure 7.3-6: Femoral head displacement at fracture for Group III (The average
values were –3.21 ± 0.59 mm for Normal, -2.95 ± 0.33 mm for Ovx, -2.83 ± 0.36 mm
Ovx-NaCl, and –2.71 ± 0.78 mm for Ovx-Ris.)
All Three Test Groups:
Data from all three test groups were compiled (tables 7.3-1, 7.3-2, and 7.3-3),
and the results were compared, but there were no significant differences, as shown in
figures 7.3-7 and 7.3-8.
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Figure 7.3-7: Femoral neck ultimate strength for all three groups (The average values
were 1060 ± 239.3 N for Normal, 1225.8 ± 220.3 N for Ovx, 1138.3 ± 188.1 N for
Ovx-NaCl, and 1116.7 ± 264.7 N for Ovx-Ris.)
0

Ovx-Ris

Ovx-NaCl

-1.5

Normal

Displacement (mm)

-1

Ovx

-0.5

-2

-2.5

-3

-3.5

-4

Figure 7.3-8: Femoral head displacement at time of fracture for all three groups (The
average values were –2.96 ± 0.60 mm for Normal, -3.08 ± 0.32 mm for Ovx, -2.60 ±
0.37 mm for Ovx-NaCl, and –2.45 ± 0.75 N for Ovx-Ris.)
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7.4 Histomorphometric Results
The porosity was measured for Groups I and II, but there was no significant
difference between treatment groups as shown in figures 7.4-1 and 7.4-2.
3.5

3

Porosity (%)

2.5

2

1.5

Ovx

0.5

Normal

1

0

Figure 7.4-1: Porosity Percentage (Po) for Group I (The average values were 1.86 ± 0.74 for
Normal, and 2.10 ± 1.07 for Ovx.)
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0.5

0

Figure 7.4-2: Porosity Percentage (Po) for Group II (The average values were 2.86 ± 0.64
for Ovx-NaCl, and 2.88 ± 0.82 for Ovx-Ris.)
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7.5 DEXA Scan Results
Table 7.5-1: DEXA Scan results from OSU and Analysis
Number
19
20
22
23
Avg
Avg/kg

Weight
kg
4.9
4.4
5.1
4.8
4.8

Total
Proximal 1/3
BMD
BMC
Area
BMD
BMC
Area Treatment
2
2
2
2
g/cm
g
cm
g/cm
g
cm
0.458
5.694
12.443
0.381
1.974
5.185
NaCl
0.427
5.257
12.307
0.358
1.882
5.251
NaCl
0.382
4.269
11.186
0.321
1.473
4.593
NaCl
0.469
5.046
10.751
0.405
1.768
4.37
NaCl
0.434
5.0665 11.67175 0.36625 1.77425 4.84975
0.090417 1.055521 2.431615 0.076302 0.369635 1.010365

21
24
25
26
27
Avg
Avg/kg

4.8
6
4.3
3.5
3.7
4.46

0.46
5.045
10.975
0.389
1.744
4.484
0.439
5.161
11.762
0.37
1.813
4.905
0.364
0.3766
10.348
0.284
1.248
4.395
0.438
4.816
10.986
0.369
1.634
4.42
0.371
4.213
11.347
0.319
1.509
4.738
0.4144 3.92232 11.0836 0.3462
1.5896
4.5884
0.092915 0.879444 2.485112 0.077623 0.356413 1.028789

Difference
(NaCl-Ris)

0.34
Normalized

0.0196 1.14418 0.58815 0.02005 0.18465 0.26135
-0.0025 0.176077 -0.0535 -0.00132 0.013223 -0.01842

Ris
Ris
Ris
Ris
Ris

%Diff
7.62331839 4.72973 29.171 5.306489 5.79145 11.61613 5.695885
((NaClNormalized -2.68863 20.02139 -2.15272 -1.70211 3.709987 -1.79091
Ris)/Ris*100)

The BMD of the Ris group is lower than that of the Saline control group, but
when it is normalized on a per kg of body weight basis, the BMD of the Ris
specimens are 2.7% greater than the saline control rabbits. The BMD for the
proximal third of the bone is greater in the Ris group, but only by 1.8% (normalized
for body weight). There were no significant differences between treatment groups
regardless of parameter. The DEXA results when plotted against body mass shows a
slight trend, as shown in figure 7.5-1
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Figure 7.5-1: DEXA scan results versus body mass.
7.6 Weight Measurements
The weights of the animals were monitored in the injection groups because the
dose volume was determined by the weight of the animal. The weights of the other
two treatment groups were monitored for comparison purposes.
The average weight at dissection was not significantly different between any
of the groups. The change in weight from the first day of the 140 day treatment until
sacrifice was not significantly different. The percent change from the beginning
weight was, also, not significantly different for the Normal group compared to all of
the Ovx groups, and there is no significant difference for the percent change of any of
the Ovx groups, but there is the beginnings of a trend towards an increased
percentage change in mass for the Ovx groups. The relationships in mass can be seen
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in figure 7.6-1 and table 7.6-1, Group I was not included, because weekly mass data
is not available for this group.
Table 7.6-1: Mass Results for Groups II and III
Specimen Treatment Mass (kg) Change (kg) %Change
127
Normal
4.10
0.81
19.76
128
Normal
3.00
-0.10
-3.33
129
Normal
4.00
1.02
25.50
130
Normal
4.50
0.35
7.78
Average
3.90
0.52
12.43
SD
0.64
0.50
12.84
134
135
137
140

Ovx
Ovx
Ovx
Ovx
Average
SD

3.70
4.00
3.80
4.10
3.90
0.18

1.01
0.83
0.80
0.78
0.86
0.11

27.30
20.75
21.05
19.02
22.03
3.62

19
20
22
23
138
139
141
142

NaCl
NaCl
NaCl
NaCl
NaCl
NaCl
NaCl
NaCl
Average
SD

4.60
3.60
3.90
4.10
4.20
3.97
4.08
3.79
4.03
0.30

0.30
0.80
1.20
0.70
1.47
0.74
0.47
0.52
0.78
0.39

6.52
22.22
30.77
17.07
35.00
18.64
11.52
13.72
19.43
9.61

21
24
25
26
27
131
132
133
136

Ris
Ris
Ris
Ris
Ris
Ris
Ris
Ris
Ris
Average
SD

4.20
4.70
3.80
3.50
3.50
3.93
3.88
4.35
3.64
3.94
0.41

0.60
1.30
0.50
0.00
0.20
0.68
1.02
1.15
1.12
0.73
0.45

14.29
27.66
13.16
0.00
5.71
17.30
26.29
26.44
30.77
17.96
10.66
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Figure 7.6-1: Mass Results for Groups II and III
7.7 Comparison of Results
The compliance is the inverse of the slope of the linear portion of the fracture
toughness data, as shown previously. A lower compliance value implies a stiffer
material. When the compliance is plotted versus the body mass, a relationship
becomes evident as seen in figures 7.7-1 and 7.7-2.
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Figure 7.7-1: Compliance versus body mass for Group III, shown with a second degree
polynomial fit.
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Figure 7.7-2: Compliance versus body mass data for Group III, with a linear trend line
added.
To better understand the mechanisms of bone fragility in the estrogen
deficient rabbit, relationships were investigated between various experimental
measures. No significant relationships were found, other than the compliance versus
mass as shown in figures 7.7-1 and 7.7-2, but some graphs of interest are:

•

Load versus Mass for Groups II and III (Figure 7.7-3)

•

Femoral Head Displacement versus Body Mass for Groups II and III (Figure
7.7-4)

•

Femoral Head Displacement versus Body Mass for Group III (Figure 7.7-5)
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•

BMD and BMC versus Body Mass (Figure 7.7-6)

•

Stress Intensity Factor versus Po for Group I (Figure 7.7-7)

•

Stress Intensity Factor versus Po for Group II (Figure 7.7-8)

•

Po versus Body Mass for Group II and III (Figure 7.7-9).
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Figure 7.7-3: Load versus mass for Groups II and III with linear fit.
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Figure 7.7-4: Femoral head displacement data for Groups II and III versus body mass.
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Figure 7.7-5: Displacement of the femoral head at fracture of Group III versus body mass
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Figure 7.7-6: Plot of BMD and BMC versus body mass for Group II.
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Figure 7.7-7: Stress Intensity Factor versus %Po for Group I.
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Figure 7.7-8: The stress intensity factor versus the %Po for Group II.
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Figure 7.7-9: Relationship of %Po versus body mass for Group II.
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7

7.8 Torsion Testing Data (Cain, R, et al, 2003)
Another research project was being performed, using one of the tibias from
Group III, by R Cain, et al. This project was to investigate the bone composition, and
torsional values for the estrogen deficient rabbit. The results, although not
significant, show the relationship of body mass to torque and angle of fracture in
figure 7.8-1.
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Figure 7.8-1: Torsional test data versus body mass for Group III.
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CHAPTER 8: DISCUSSION
8.1 Discussion Fracture Toughness Data
The data shows a trend that the Risedronate treatment increases fracture
toughness of the bones, and this is also shown microscopically by the
histomorphometric measures, but the model does not have enough numbers to prove
statistical significance. The compliance data implies that there is a strong correlation
between body mass and bone properties, as can be seen in the figures 7.7-1, and 7.72. Hui et al. (2002) showed that decrease in bone mineral density can be offset by
increases in body mass. Bauer et al (1993), Shiraki et al (1991), Russel-Aulet et al
(1993), Klementti et al (1997), Reid et al (1995), and Felson et al (1993) have all
shown that bone mass is greatly effected by body mass. The increase in body mass of
the estrogen deficient rabbits could be a reason for the lack of difference in the
experimental groups.
Although Mashiba et al (2001) found a increase in bone mass and strength in
rabbits after only one remodeling cycle (70 days), and Hirano et al showed favorable
effects in rabbits after 140 days (1999) and after five months (2000), these results
may not apply to our study, because they used an anabolic agent and an intact rabbit
model. Lugero, et al (2000) using an overectomized rabbit model found no
significant difference in BMD in the rabbit tibia after 4 months, and believe this
maybe from the particular R/F balance dynamic of the rabbit and the need for longer
periods of time for the difference to manifest. A guinea pig take approximately 6
months for a BMD difference to be found. Cao, et al (2000) found no significant
diffence in cortical BMD after 4 and 12 weeks, but found a significant difference in
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trabecular bone mass. This experiment also found no significant difference in BMD
of the femur for Group II, and this lack of change BMD could be a reason for the lack
of difference in the fracture toughness values between groups.
Fracture toughness, as found by Yeni and others, is dependent on many
different factures and the exact mechanism for failure and the primary cause is still
not known. More study is necessary to find the mechanism of change in fracture
resistance.
8.2 Discussion of Histomorphometry Data
The bone specimens from the estrogen deficient animals would be expected to
be more porous than those from the normal control specimens. The increased
porosity would then translate to decreased fracture toughness. The results of our
testing do not show this. The lack of the hypothesized results could be from a lack of
sufficient time for the increased level of resorption to outpace formation sufficiently
for a greater amount of porosity than the normal control.
8.3 Discussion of Femoral Neck Data
The femoral neck data showed a decrease in stiffness, but not a decrease in
ultimate strength, since the ultimate load at fracture was not significantly different,
but the displacement of the femoral head was significantly larger for the Ovx control
groups, when compared to Normal and Ovx-Ris. This data is similar to that found by
Bagi, et al (1997) in their paper about femoral neck strength of estrogen deficient rats.
The Ovx animals in their study had a significantly lower BMD at the end of their
study (12 weeks), but the ultimate strength was not significantly different between the
Normal and Ovx groups, but the Ovx group was significantly less stiff. Crabtree et al
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(2001) found that the main factor in hip fracture was cortical bone and not trabecular
bone as it would have been thought. The relatively slower change of the cortical bone
in the rabbits could be a reason for the lack of difference in ultimate strength, even if
stiffness may decrease, which could be due to architectural changes of the trabecular
bone.
8.4 Discussion of BMD testing of bones
The BMD in Group II found from DEXA were not significantly different
between groups, but the BMD has a slight correlation with the fracture toughness
values, but does not have a high level of significance. The lack of significance could
be from a lack of numbers, or there may not be a relationship, but the relationship has
been well established, so it is likely the former and not the latter.
The BMC’s found by Ruthanne Cain, et al (2003) for Group III were not
significantly different for any treatment group, which implies that the 140 day time
period may not be long enough for a difference to be detected by the test. The sample
size may also be too small, since the beginning BMD is not known, and the lack of
difference could be caused by chance, since the peak BMD for each animal differs.
Lugero, et al (2000) using an overectomized rabbit model found no significant
difference in BMD in the rabbit tibia after 4 months, and believe this maybe from the
particular R/F balance dynamic of the rabbit and the need for longer periods of time
for the difference to manifest. A guinea pig take approximately 6 months for a BMD
difference to be found. Cao, et al (2000) found no significant difference in cortical
BMD after 4 and 12 weeks, but found a significant difference in trabecular bone
mass.
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8.5 Discussion of Weights
The body mass of the animal seems to be a very important parameter in
considering the properties of the bones. The animals in the Ovx groups gained a
larger percentage of weight than their non-Ovx (intact) counterparts. Estrogen
deficiency causes a decrease in bone mineral density, through an increase in bone
resorption. Estrogen deficiency also cause and increase in body mass, which has
been shown to cause an increase in bone mineral density. For the Ovx control
groups, the two effects on BMD may have been offsetting, such that the bone quality
was not significantly different than that of the normal rabbit. The Ovx animals
treated with risedronate had the increase in body mass, which would cause an
increase in BMD, but the drugs counteracts the increased resorption caused by
estrogen deficiency, thus the net change in BMD is positive, since there is no negative
change to cause a decrease in properties. The changes are evident in the comparisons
of fracture toughness, histomorphometric properties, and to some extent, the stiffness
values from the femoral neck testing.
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8.6 Limitations
Limitations of this study include:
1. The number of specimens is relatively low for the amount of scatter in the data. A
larger sample size may bring about significance.
2. The effects of machining on the fracture toughness of the specimens is not known.
The methodology of machining is the same for each specimen, so it should not effect
results for the comparison within groups.
3. The specimens do not satisfy all of the ASTM requirements for fracture toughness
test specimens, so they cannot be compared to other engineering materials.
4. A razor blade was used to initiate the precrack. The use of the razor blade to initiate
the crack may affect toughness, and this type of crack may not be seen in vivo.
5. The period of time (20 weeks) may not have been sufficiently long to be able to see
mechanical differences between treatment groups.
6. Bone Mineral Density was not tested at the beginning of the experiment. The final
BMD may or may not have changed, and the peak density could have affected the
outcome.
7. Blood and/or urine samples were never taken for testing of Calcium levels as a
marker of bone turnover.
8. No dynamic histomorphometry of these bones were performed. The successful use of
markers could give insight into the mechanisms of estrogen deficiency and drug
treatment on resorption and formation.
9. The body composition and its change with ovariectomy and time are not known
10. The levels of circulating hormones were never measured.
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11. No cancellous bone histomorphometry was performed to perhaps explain some of the
femoral neck fracture data.
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8.7 Recommendations for Future Study
Although this study has expanded the knowledge of the use of an
ovarectomized rabbit model, and in the testing of bone specimens from said model,
other relationships and causes for observations should be investigated. Some
suggestions for future investigation include, but not limited to:
1. Analyze the biochemical parameters of the tibia and femur. Some of the
differences in fracture toughness may be do to the collagen makeup.
Biochemical analysis may also lend insight to the effect of bisphosphonates
on the rabbit bone physiology.
2. Investigate other machining methods. Care and research went into the design
of the machining procedure, but this does not mean that the technique is
perfected.
3. Dynamic histomorphometry should be performed. Dynamic
histomorphometry would allow for the study of mineralization rates, and their
effect on fracture toughness.
4. Bone mineral density should be measured at the beginning of the experiment
to investigate BMD change and the changes effect on fracture toughness.
5. Characterize the femoral neck and head geometry. The archetetural of the
head and neck region could have a major effect on the strength and rigidity of
the structure.
6. Determine clinical applications for predicting fracture in humans.
7. Use varying lengths of time for testing, including tests of longer duration to
determine the change in fracture toughness with time after ovarectomy.
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8. Investigate the blood hormone levels, since estrogen is an important hormone,
but it is not the only regulating hormone.
9. Measure the body composition of the animals, and determine if this has an
effect on the fracture toughness, and/or the circulating levels of hormones.
10. Perform histomorphometry of the trabecular bone, to determine if the change
effects the femoral neck fracture results.
11. Investigate other material tests, including other fracture modes, and whole
bone tests, such as three point bending.
12. Fracture toughness of Ovx and Ovx-Ris bone should be investigated in other
directions, besides just the longitudinal direction, since the bone fibers may be
reorienting themselves with the new loading enviroment.
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8.8 Contributions
This study contributed to the expanding knowledge of fracture toughness of
estrogen and drug treated rabbits in the following ways.
1. There is a correlation between the compliance and the body mass of the animal.
2. There seems to be a relationship between fracture type and body mass.
3. Various testing procedures were standardized, which could allow future testing.
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APPENDIX A: H & E STAINING PROCEDURE
This procedure is for H & E staining of plastic embedded bone sections of 80
– 100 µm, that have been subsequently ground and polished to a final thickness of
~50 µm.
The section is first rinsed in water, and then allowed to soak in Harris’
Hematoxylin for 15 minutes on a platform shaker at 95 rpm. The section is then
placed in gently running water for five minutes. After the rinse, the section is dipped
gently 20 times in Acid Alcohol, which is a solution of 10 ml HCL to 1990 mL of
distilled water. The specimen is then placed in a running water rinse for 8 minutes.
The specimen is then dipped gently 15 times in Ammonia Water, which is a solution
of 3 mL ammonium hydroxide to 1000 mL tap water. The specimen is again placed
in a running water rinse for 15 minutes. After the rinse, the specimen soaked in Eosin
for 6 minutes. After the Eosin bath, the specimen goes through a series of dipping in
order 80% Alcohol, 95% Alcohol, 100% Alcohol, 100% Alcohol, Xylene for 10, 15,
15, 15, and 15 dips respectively.
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APPENDIX B: PLASTIC EMBEDDING PROCEDURE
Introduction:
Microscopic investigation necessitates the thin sectioning of the material that
is desired to be studied. The problem of sectioning is multifaceted, since often the
material sample, although large by microscope terms, is much too small for
conventional machining techniques. Fragility of the structures, which are desired for
investigation, also pose a problem, since these can be destroyed during the sectioning
process.
Plastic embedding of the material is one way that these limitations can be overcome.
The plastic gives support to the sectioned structures, which helps keep them from
being destroyed, and it gives extra length and width such that the specimen can be
clamped and sectioned.
Procedure:
1. Specimens are fixed in 10% neutral buffered formalin.
2. The specimens are place in a Hypercenter XP tissue processor (Shandon,
Pittsburgh, PA) for processing which includes:
a. Dehydration in alcohol
b. Clearing with Xylene
c. Infiltration with methymethacrylate (MMA)
3. Specimens are embedded in MMA (100 ml MMA to 0.2 g Perkadox)
4. Specimens are left in vacuum oven for 1-2 hours to remove air bubbles
5. Specimens are place in water bath (36 oC) overnight for polymerization
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APPENDIX C: MMA EMBEDDED CROSS-SECTION POLISHING PROCEDURE
1. Cut Sections From Plastic Embedded Bone. Make the cuts at 45 marks
(450 µm), which will give a final thickness of 120 µm.
2. Store the sections in plastic cassettes labeled with the specimen number
in a large beaker of distilled water.
3. Use forceps to pick up the specimen and
gently place on the 800# sandpaper. Spray a
small puddle of distilled on the sand paper.
Begin polishing circular motion, add some
pressure. Keep polishing for four mins. Turn
over three times (1 min 20 sec per side).

4. Put the specimen on the nylon cloth. Spray
2-3 drops of 3 micron polishing solution
(green) on the cloth. Polish using circular
motion. Polish for 6 minutes, turning three
times (every 2 mins).

Gently pick up the
specimen, and dip
it in a beaker #1 of
distilled water 5
times, then beaker
#2 of distilled
water 5 more times.

5. Put the specimen on the second nylon
cloth. Spray 2-3 drops of 1 micron polishing
solution (blue) on the cloth. Polish with
circular motions. Polish for 4 minutes. Turn
over three times (1min 20 sec per side).

6. Put the specimen on the microcloth, spray
with a few drops of distilled water. Polish
with circular motions for 2 mins., turning over
once (1 min per side).
7. Dry the specimen on a napkin for approximately five minutes. Check on the
microscope 40x to make sure there are no scratches. If there are scratches
repeat steps three through five. If there are not scratches mount on a slide
labeled with the specimen number with flourmount and cover slip. If it is to be
stained, place the specimen back in the cassette and store in a small beaker of
distilled water.
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APPENDIX D: IN-VIVO STAIN PREPARATION
Two different stains were used in this study for the purpose of dynamic
histomorphometry, tetracycline and Calcein.
Tetracycline:
1. Mix 2.5 grams of powdered tetracycline in 100 ml of phosphorous buffered saline
(PBS).
2. Stir using magnetic stirrer for several minutes (15 – 30 mins).
3. Use buffers to bring the pH to normal biological level (7.4). Note: This step is very
important, because tetracycline is very acidic.
4. Using filters put the solution into sterile vials.
5. Refrigerate (4 oC) until used.
6. Dosing is give in the same manner as the risedronate 1ml/kg
7. Injections can be given subcutaneously or intraperitoneally.
Calcein:
1. Make 100 ml of 2% sodium bicarbonate and distilled water (2 mg NaH2CO3 in 100
ml of distilled water).
2. Mix 1.5 grams of powdered calcein in 100 ml of the solution made in step 1.
3. Stir using a magnetic stirrer for several minutes (15-30 mins).
4. Using filters put the solution into sterile vials
5. Refrigerate (4 oC) until used
6. Dosing is given in the same manner as the risedronate 1 ml/kg.
7. Injections can be given subcutaneous or intraperitoneal.
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